| Literature DB >> 33847188 |
Kyra Theunissen1,2,3, Guy Plasqui1, Annelies Boonen2, Bente Brauwers1, Annick Timmermans3, Pieter Meyns3, Kenneth Meijer1, Peter Feys3,4.
Abstract
BACKGROUND: Persons with multiple sclerosis (pwMS) experience walking impairments, characterized by decreased walking speeds. In healthy subjects, the self-selected walking speed is the energetically most optimal. In pwMS, the energetically most optimal walking speed remains underexposed. Therefore, this review aimed to determine the relationship between walking speed and energetic cost of walking (Cw) in pwMS, compared with healthy subjects, thereby assessing the walking speed with the lowest energetic cost. As it is unclear whether the Cw in pwMS differs between overground and treadmill walking, as reported in healthy subjects, a second review aim was to compare both conditions.Entities:
Keywords: cost of walking; energy expenditure; energy metabolism; gait; multiple sclerosis; walking
Mesh:
Year: 2021 PMID: 33847188 PMCID: PMC8135251 DOI: 10.1177/15459683211005028
Source DB: PubMed Journal: Neurorehabil Neural Repair ISSN: 1545-9683 Impact factor: 3.919
Figure 1.PRISMA flow diagram for study selection depicting the number of records identified, included and excluded, and the reasons for exclusions.
Characteristics of Included Studies[a].
| Publication | MS subject characteristics | Disease characteristics | Walking aid and equipment | Walking speed | Cost of walking | VO2 during walking | Healthy subject characteristics | Walking speed | Cost of walking | VO2 during walking |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Chung (2016)[ | n = 10 (9 females) | EDDS 4.6 | Treadmill | 0.60 | 0.33[ | n.s. | 14 (11 females) | 0.6 | 0.22[ | n.s. |
| Franceschini (2010)[ | n = 46 (27 females) | EDSS 3[ | Overground | 1.13 ± 0.25 | 0.19 ± 0.05 | 12.6 ± 2.5 | n = 36 (21 females) | 1.61 ± 0.18 | 0.17 ± 0.03 | 16.6 ± 3.7 |
| Motl (2011)[ | n = 18 (14 females) | PDDS 1[ | Treadmill | 0.90 | 0.20 ± 0.02 | n.s. | 18 (n.s.) | 0.90 | 0.19 ± 0.01 | n.s. |
| Motl (2009)[ | n = 24 (20 females) | PDDS 1.5 ± 1.4 | Treadmill | 0.89 | 0.21[ | 11.3 ± 1.43 | 24 (20 females) | 0.89 | 0.19[ | 9.98 ± 0.53 |
| Olgiati (1986)[ | n = 24 (10 females) | n.s. | Treadmill | 0.56 | 0.44[ | 14.6 ± 3.3 | 20 (9 females) | 0.56 | 0.29[ | 9.7 ± 1 |
| Olgiati (1988)[ | n = 33 (n.s.) | n.s. | Treadmill | 0.49 | 0.43[ | n.s. | n = 12 (6 females) | 0.49 | 0.32 | n.s. |
| Paul (2008)[ | n = 12 (n.s.) | n.s. | Overground | 0.43 ± 0.15 | 0.44 ± 0.16 | 10.43 ± 2.52 | n = 12 (n.s.) | 0.43 ± 0.15 | 0.31 ± 0.11 | 7.26 ± 1.47 |
| Sandroff (2012)[ | n = 43 (38 females) | PDDS 1[ | Treadmill | 0.90 | 0.20 | 10.8 ± 1.4 | 43 (38 females) | 0.90 | 0.19 | 10.1 ± 1.5 |
|
| ||||||||||
| Agiovlasitis (2016)[ | n = 58 (48 females) | EDDS 4.3 | Walking aid | 0.75 ± 0.16 | 0.22[ | 9.94 ± 2 | ||||
| Bregman (2012)[ | n = 6 (3 females) | n.s. | n.s. (no) | 0.95 ± 0.22 | 0.19 ± 0.04 net | n.s. | ||||
| Franceschini (2013)[ | n = 50 (33 females) | EDSS 2.79 | Walking aid | 0.78 ± 0.38 | 0.42 ± 0.63 | 11.36 | ||||
| Jeng (2018)[ | n = 44 (38 females) | PDDS[ | Walking aid | 0.95 ± 0.44 | 0.17 ± 0.07 net | n.s. | ||||
| Kalron (2019)[ | n = 88 (50 females) | EDSS 2 ± 1.5 | n.s. | 1.09 ± 0.21 | 0.19[ | 12.17 ± 2.87 | ||||
| Kalron (2019)[ | n = 66 (32 females) | EDDS 2.2 ± 1.3 | No walking aid | 1.06 ± 0.22 | 0.21 ± 0.06 | 17.19 ± 4.01 | ||||
| Miller (2016)[ | n = 20 (10 females) | EDSS 5.3 ± 2[ | Walking aid | 0.69 ± 0.31 | 0.36 ± 0.2 | 11.96 ± 3 | ||||
| Motl (2011)[ | n = 24 (n.s.) | PDDS 1[ | Walking aid | 1.07 ± 0.21 | 0.17 ± 0.04 | n.s. | ||||
| Motl (2010)[ | n = 26 (22 females) | PDDS 1.8 ± 1.6 | Walking aid | 1.20 ± 0.34 | 0.19 ± 0.09 | n.s. | ||||
| Motl (2013)[ | n = 256 (208 females) | EDSS 4 ± 3.5[ | Walking aid | 1.20 ± 0.4 | 0.23 ± 0.12 | n.s. | ||||
| Pilutti (2012)[ | n = 168 (130 females) | PDDS 3 ± 3[ | Walking aid | 1.17 ± 0.38 | 0.23 ± 0.12 | n.s. | ||||
| Rampello (2007)[ | n = 19 (14 females) | EDSS 3.5[ | Walking aid | 0.84 ± 0.3 | 0.20 ± 0.07 | n.s. | ||||
| Renfrew-Miller (2018)[ | n = 78 (50 females) | EDSS 5 | n.s. | 0.7 ± 0.24 | 0.31 ± 0.15 | n.s. | ||||
| Renfrew (2019)[ | n = 79 (51 females) | EDSS 5.1 ± 1.4 | Walking aid | 0.68 ± 0.24 | 0.31 ± 0.15 | n.s. | ||||
| Sandroff (2014)[ | n = 54 (45 females) | EDDS 4[ | Walking aid | 0.76 ± 0.28 | 0.20[ | 9.88 ± 1.93 | ||||
| Sandroff (2014)[ | n = 82 (63 females) | PDDS 3[ | Walking aid | 1.16 ± 0.42 | 0.20[ | 13.9 ± 3.8 | ||||
| Sebastião (2018)[ | n = 86 (66 females) | EDDS 3.5 ± 3.3[ | Walking aid | 1.16 ± 0.43 | 0.20[ | 13.8 ± 3.8 | ||||
|
| ||||||||||
| Agiovlasitis (2016)[ | n = 18 (14 females) | PDDS 1[ | No walking aid | 0.89 | 0.25 | n.s. | ||||
| Agiovlasitis (2016)[ | n = 43 (38 females) | PDDS 1[ | No walking aid | 0.89 | 0.20[ | 10.8 ± 1.4 | ||||
| Motl (2012)[ | n = 44 (38 females) | PDDS 1[ | No walking aid | 0.9 | 0.20[ | 10.8 ± 1.4 | ||||
| Newman (2007)[ | n = 16 (13 females) | n.s. | Walking aid | 0.28 | 0.43[ | n.s. | ||||
Abbreviation: n.s., not specified. Subject characteristics: number (female); age; height; weight, Disease characteristics: Expanded Disease Disability Scale (EDSS)/Patient Determined Disease Step (PDDS); disease duration; Primary Progressive (PP), Secondary Progressive (SP), Relapsing Remitting (RR); Walking condition: surface, (passive) walking aid allowed such as canes and walkers, metabolic system; Walking speed: meters per second (m/s); Cost of walking: gross milliliter oxygen per kilogram bodyweight per meter (mL O2/kg/m); Oxygen consumption during walking (VO2): milliliter per kilogram bodyweight per minute (mL/kg/min).
All characteristics are presented as mean or median values and in case available ± standard deviations.
Indicates conversion from net to gross Cw by summing the resting O2 consumption.
Indicates calculation Cw from data available in article.
Study-Specific Assessment of the Modified NIH Quality Assessment Tool (14 Item Across 3 Domains)[a].
| Bias domain | Clear study objective | Risk of bias | Accuracy of outcome and exposure | Clear study objective | Risk of bias | Accuracy | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author, year | Item description | 1. Research question | 2. Study population | 3. Participation rate | 4A. Recruitment | 4B. Inclusion–exclusion | 9. Blinding | 10. Confounding | 5. Sample size calculation | 6. Levels of exposure | 7A. Description exposure | 7B. Reliability exposure | 8A. Description outcome | 8B. Reliability outcome | 8C. Comparison across studies | Domain score | ||
| Chung (2016)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Franceschini (2010)[ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||
| Motl (2011)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Motl (2009)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Olgiati (1986)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Olgiati (1988)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Paul (2008)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||
| Sandroff (2012)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Agiovlasitis (2016)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Bregman (2012)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||
| Franceschini (2013)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Jeng (2018)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Kalron (2019)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Kalron (2019)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Miller (2016)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Motl (2011)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Motl (2010)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Motl (2013)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Pilutti (2012)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Rampello (2007)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Renfrew-Miller (2018)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Renfrew (2019)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||
| Sandroff (2014)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Sandroff (2014)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Sebastião (2018)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Agiovlasitis (2016)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Agiovlasitis (2016)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Motl (2012)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Newman (2007)[ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
Cells with a check mark indicate a “yes” reported. Blanks are items reported as no/not reported. The overall domain score in light grey indicates “good” quality, medium grey indicates “moderate” quality, and dark grey indicates “poor” quality.
Figure 2.(a) Cost of walking for all studies including persons with multiple sclerosis. (b) Cost of walking for all studies including healthy subjects. (c) Cost of walking for all studies including persons with multiple sclerosis in overground walking conditions. (d) Cost of walking for all studies including persons with multiple sclerosis in treadmill walking conditions.